In Vitro and In Vivo Activities of Ruthenium(II) Phosphine/Diimine/Picolinate Complexes (SCAR) against Mycobacterium tuberculosis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Pavan, Fernando R ^a   Poelhsitz, Gustavo V ^b   da Cunha, Lucas V P ^c   Barbosa, Marilia I F ^c   Leite, Sergio R A ^a   Batista, Alzir A ^c   Cho, Sang H ^c   Franzblau, Scott G ^d   de Camargo, Mariana S ^a   Resende, Flávia A ^a   Varanda, Eliana A ^a   Leite, Clarice Q F ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; IMINE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PHOSPHINE; PICOLINIC ACID; RIFAMPICIN; RUTHENIUM COMPLEX; STREPTOMYCIN;

ACUTE TOXICITY; AMES TEST; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LD 50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTAGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANIMALS; ANTITUBERCULAR AGENTS; COORDINATION COMPLEXES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; IMINES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; MUTAGENICITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHOSPHINES; PICOLINIC ACIDS; RUTHENIUM; TOXICITY TESTS, ACUTE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84878384875     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064242     Document Type: Article

References (35)

1. Hunter JH, Pang CKT, Gujjar R, Rathod PK, (2008) Kinetics and Ligand-Binding Preferences of Mycobacterium tuberculosis Thymidylate Synthases, ThyA and ThyX. Plos One 3: e2237.
2. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K, (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
3. Raviglione MC, (2006) The global plan to stop TB, 2006-2015. International Journal of Tuberculosis and Lung Disease 10: 238-239.
4. Ma ZK, Lienhardt C, McIlleron H, Nunn AJ, Wang XX, (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet 375: 2100-2109.
5. Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, et al. (2010) Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 54: 4150-4158.
6. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.
7. Pavan FR, Sato DN, Leite CQF (2011) An approach to the search for new drugs against tuberculosis. In: Cardona P-J, editor. Mycobacterium tuberculosis/book 2: Intech.
8. Munos B, (2009) Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8: 959-968.
9. Swinney DC, Anthony J, (2011) How were new medicines discovered? Nature Reviews Drug Discovery 10: 507-519.
10. Bernersprice SJ, Norman RE, Sadler PJ, (1987) The autoxidation and proton dissociation-constants of tertiary diphosphines- relevance to biological-activity. Journal of Inorganic Biochemistry 31: 197-209.
11. Pavan F, Von Poelhsitz G, do Nascimento F, Leite S, Batista A, et al. (2010) Ruthenium (II) phosphine/picolinate complexes as antimycobacterial agents. European Journal of Medicinal Chemistry 45: 598-601.
12. Pavan FR, Poelhsitz GV, Barbosa MIF, Leite SRA, Batista AA, et al. (2011) Ruthenium(II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis. European Journal of Medicinal Chemistry 46: 5099-5107.
13. do Nascimento F, Von Poelhsitz G, Pavan F, Sato D, Leite C, et al. (2008) Synthesis, characterization, X-ray structure and in vitro anti mycobacterial and antitumoral activities of Ru(II) phosphine/diimine complexes containing the "SpymMe(2)" ligand, SpymMe(2) = 4,6-dimethyl-2-mercaptopyrimidine. Journal of Inorganic Biochemistry 102: 1783-1789.
14. Queiroz SL, Batista AA, Oliva G, Gambardella M, Santos RHA, et al. (1998) The reactivity of five-coordinate Ru(II)(1,4-bis(diphenylphosphino)butane) complexes with the N-donor ligands: ammonia, pyridine, 4-substituted pyridines, 2,2'-bipyridine, bis(o-pyridyl)amine, 1,10-phenanthroline, 4,7-diphenylphenanthroline and ethylenediamine. Inorganica Chimica Acta 267: 209-221.
15. Collins LA, Franzblau SG, (1997) Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrobial Agents and Chemotherapy 41: 1004-1009.
16. Miyata M, Pavan FR, Sato DN, Marino LB, Hirata MH, et al. (2011) Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: Phenotypic and genotypic methods. Biomedicine & Pharmacotherapy 65: 456-459.
17. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, et al. (2002) Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 46: 2720-2722.
18. Cho SH, Warit S, Wan BJ, Hwang CH, Pauli GF, et al. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 51: 1380-1385.
19. Changsen C, Franzblau SG, Palittapongarnpim P, (2003) Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrobial Agents and Chemotherapy 47: 3682-3687.
20. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, et al. (1999) Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infection and Immunity 67: 4586-4593.
21. Wayne LG, (1994) Dormancy of Mycobacterium-tuberculosis and latency of disease. European Journal of Clinical Microbiology & Infectious Diseases 13: 908-914.
22. Wayne LG, Hayes LG, (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infection and Immunity 64: 2062-2069.
23. Wayne LG, Sohaskey CD, (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annual Review of Microbiology 55: 139-163.
24. Moody JA (1992) Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: HD I, editor. Clinical microbiology procedures handbook. Washington, DC: American Society for Microbiology. 1-28.
25. Luna-Herrera J, Costa MC, Gonzalez HG, Rodrigues AI, Castilho PC, (2007) Synergistic antimycobacterial activities of sesquiterpene lactones from Laurus spp. Journal of Antimicrobial Chemotherapy 59: 548-552.
26. Poeta MD, Cruz MC, Cardenas ME, Perfect JR, Heitman J, (2000) Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrobial Agents Chemotherapy 44: 739-746.
27. Organisation for Economic Co-operation and Development (OECD). Available: http://www.oecd.org/publications. Acessed 2013 Jan 3.
28. Maron DM, Ames BN, (1983) Revised methods for the Salmonella mutagenicity test. Mutation Research 113: 173-215.
29. Bernstein L, Kaldor J, McCann J, Pike MC, (1982) An empirical-approach to the statistical-analysis of mutagenesis data from the Salmonella test. Mutation Research 97: 267-281.
30. Santos FV, Colus IMS, Silva MA, Vilegas W, Varanda EA, (2006) Assessment of DNA damage by extracts and fractions of Strychnos pseudoquina, a Brazilian medicinal plant with antiulcerogenic activity. Food and Chemical Toxicology 44: 1585-1589.
31. Handbook of anti-tuberculosis agents. Tuberculosis 88: 85-169.
32. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun ZH, (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. Journal of Antimicrobial Chemotherapy 52: 790-795.
33. Russell DG, (2001) Mycobacterium tuberculosis: Here today, and here tomorrow. Nature Reviews Molecular Cell Biology 2: 569-577.
34. Conde MB, de Melo FA, Marques AMC, Cardoso NC, Pinheiro VGF, et al. (2009) III Brazilian Thoracic Association Guidelines on Tuberculosis. Jornal Brasileiro De Pneumologia 35: 1018-1048.
35. Mortelmans K, Zeiger E, (2000) The Ames Salmonella/microsome mutagenicity assay. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 455: 29-60.